ABSTRACT
INTRODUCTION
E pigcnctics involves the study of changes in the regulation of gene activity and expression, independent of gene sequences. Post-translational mod ifications of histones, including methylation, acetylation, phosphorylation, and ubiquitination, arc all important epigenetic factors. Histo ncs arc proteins around which DNA is wound for compaction and gene regulation. Two copies each of histones H2A, I-128, H3, and H4 assemble to form one nucleosome core, which is wrapped by -146 base pairs of DNA. Histone HI binds the nuclcosome at the entry and exit sites of the DNA and locks it into place. 1 The tight nucleosome structure helps to pack the enti re genome into the cell nucleus and can restrict the access of nuclear factors to the DNA. This inherently restrictive environment must be tightly regulated to ensure that permissive cellul ar processes such as gene transcription, repl ication, recombination, and repair occur only under the appropriate circumstances. Because the dysfunction of these systems is inherent in many disease states, epigenetics has become an emerging frontier fo r drug discovery.
The human genome encodes more than 70 enzymes that catalyze the methylation of lysine (Lys, K) or arginine (Arg, R) residues on histones HI , H2A, H2B, H3, and 1-14. They are collectively referred to as histone methyltransferases (HMTs). HMTs mainly methylate histones using S-adenosyl-L-methionine (AdoMet or SAM) as a methyl donor.2.J Most histone lysine methyltransferascs (HKMTs) contain a SET -domain [Su(var)3-9, Enhancer ofZeste, and Trithorax]. The only known HKMTs that lack the SET domain are the members of the DOT! fam ily. 1 Irregular expression of HKMTs is associated with hu man cancers.5·6 Enhancer of zeste homolog 2 (EZH2) is ubiquitously expressed during early embryogenesis, and becomes restricted to the central and peripheral nervous systems and the sites of feta l hematopoiesis during later dcvelopment. 7 EZH2 is responsible for the methylation of Lys 27 of histone H3 8 as well as that of Lys 26 on histone H 1. 9 Ovcrexpression of EZH2 is found in many cancers: prostate (metastatic), breast, liver, bladder, colon, skin, and lung, among others. However, surprising fi ndings by Ernst and colleagues 10 have suggested that EZI-12 is a tumor suppressor in myeloid malignancies. G9a and G9a-like protein (GLP), the two highly homologous HKMTs, methylate Lys 9 of histone H3 and have also recently been reported to inactivate p53 via methylation of Lys 373.
been discovered thus far: PRMT 1-PRMT I I. 14 All of these enzymes display conserved sequence motifs in the catalytic domain, although methyl transferase activities have not yet been confirmed for PRMTIO and PRMTII. The PRMT enzymes have been classified according to the nature of the dimcthylated arginine reaction product. The type-I PRMT enzymes catalyze the formation of monomcthyl arginine (MMA) and asymmetric dimethyl arginine, while the type n PRMT enzymes fo rm MMA and symmetric dimethyl arginine. The enzymes PRMT I, PRMT2, PRMT3, PRMT4, PRMT6, and PRMT8 belong to the type I group, whereas PRMT5, PRMT7, and PRMT9 arc type n enzymcs. 1 5-18 Arginine methylation is an abundant post-translational modification that regulates a diverse array of cellular functions. The list of proteins known to be methylated on arginine has grown rapidly over the past decade and now includes hundreds of proteins. Recently identified PRMT substrates include nudcolin, fibrillarin, and hclicascs. 17 · 19 Various biochemical and biological processes such as signal transduction, proliferation, transcriptional regulation, and RNA splicing are known to involve arginine methylation. In addition to the important role of PRMTs in norm al cellular fu nction, dysregulatcd PRMT activities are implicated in disease processes such as certai n cancer types, cardiovascular disease, multiple sclerosis, and spinal muscular atrophy. 20 -22 Due to the role of HMTs as important epigenetic regulators and their dear link to human cancers, HMTs have generated intense interest as drug discovery targets. Although many HMT assay formats arc currently available, each has its own particular pros and cons (see the Discussion section), and there is no widely accepted highthroughput screening (HTS) assay format. In an effort to fill this gap, we have produced enzymes and applied a modified miniaturized radioisotope-based filter-binding assay for ITMTs. HotSpotsM. originally developed for kinases, 21 " 24 can be performed at the low costs necessary to serve the drug discovery market. This platform detects total methylation of any substrate on both lysine and arginine residues. Substrates ranging from peptides to nuclcosomcs can be used without the need for modification; therefore, U1is pl atform is suitable for ultrahigh-throughput screening (uHTS) and selectivity profiling against a large panel ofHMTs. Here we will show the results ofHMT studies performed with this platform. The data indicate that this format enables HTS of HMTs as well as compou nd evaluations and ki netic studies.
MATERIALS AND METHODS

Ma terials
Human DOTIL (residues 1-4 16; accession II NM_032482) was expressed in Escllericllia coli as N-terminal GST fusions. Human recombinant EZH I (residues 2-747; Gcnbank Accession II NM_OOI99 1) or EZH2 (residues 2-746; Genbank Accession II NM_OOI203247) were coexpressed with human recombinants AEBP2 (2-5 17; NM_OOIII4 176), EED (2-44 1; NM_003797), RbAp48 (2-425; NM_005610), and SUZ I2 (2-739; NM_OI53 55) in an insect cell/baculovirus expression system to form the 5-member EZH I or EZI-12 complexes. All proteins were full length (residue 2 through Cterminus). The EED subunit incorporated an N-terminal Flag-tag, and 2 ASSAY and Drug Development Technologies xxxx 2013 all others included anN-terminal His-tag. Human GLP (residues 894-1298; accession II NM_024757) and Human G9a (residues 786-121 0; accession II NM_006709) were expressed as N-terminal GST fusion protein in E. coli. Human MlL I (residues 3745-3969; accession II NM_005933), human WDR5 (22-334; NM_OI7588), RbBP5 (1-538; NM_005057), Ash2L (2-534; NM_00 1105214). and OPY-30 (1 -99; NM_0325742) were expressed in E. coli with N-tcrminal His-tags assembled as a complex and stored in 20 mM Tris-HCI, pH 7.5, 300 mM NaCI, I mM TCEP, 10% (w/v) glycerol, and I ~1M ZnCI 2 • Human MLL2 (residues 53 19-5537; accession # NM_003482), human MLLJ (residues 4689-49 11 ; accession # NM_ I70606), and human MLL4 (residues 2490-27 15; accession II NM_O 14727) were expressed in E. coli with N-terminal His-tags, and SET I B (residues 1629-1923; accession II NM_O 15048) was expressed in E. coli with N-tcrminal GST-tag. All four were assembled in complexes as MLLI , as mentioned above. Human recombinant NSD2 (residues 2-1365; accession II NM_OO 1042424) was expressed with an N-tcrminal Histag in an insect cell/baculovirus expression system. Human recombinant SUV39H I (residues 44-4 12; accession II NM_003 173) and SUV39H2 (residues 48-4 1 0; accession II NM_OO 1193424), both with C-terminal His-Tags, were ex pressed in E. coli. The following enzymes were codcvclopcd or purchased from BPS Bioscicnccs: E. coli expressed SET7, His-tagged, full length; SETS, GST-taggcd aa l95-352; PRMTI, GST-tagged aa2-end; PRMT3, GST-taggcd aa2-cnd ; PRMT6, and His-tagged aa2-end, and Free Style"' 293-F cells (human kidney line; Invitrogen) expressed SETMAR, Flag-tagged aa 14-end; PRMT4, Flag-tagged aa2-cnd; and PRMT5, Flag-tagged aa2-end.
Nudcosomcs were prepared from Hela according to Schnitzler. 
Me thyltra nsferase Assay
Methyltransferase assays were performed in the radioisotopebased llotSpot formal as described previously2 3 • 24 with the following modifications. The reaction buffer for EZH I and EZH2 was 50 mM Tris-HCI, pH 8.0, 50 mM NaCI, I mM EDT A, I mM OTT, I mM PMSF, and 1% DMSO. The reaction buffer for all other HMTs was 50 mM Tris-HCI, pH 8.5, 50 mM NaCI, 5 mM MgCI 2 , I mM OTT, I mM PMSF, and I% DMSO. Standard substrate concentrations were 5 J.lM peptide or protein substrate, and I J.lM SAM, unless otherwise mentioned. For control compound IC 50 determinations, the test compounds were diluted in DMSO, and then added to the enzyme/substrate mixtures in nanoliter amounts by using an acoustic technology (Echo550; Labcyte). The react ion was in itiated by the addition of 3 H-SAM, and incubated at 30°( for I h. The reaction was detected by a filterbinding method. Data analysis was performed using Graph Pad Prism software for curve fits, and GraFit (Erithacus) for gl obal lit of kinetic studies using the ternary complex equation:
used in approaches that monitor SAM consumption and/o r SAH production.
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Each lysine-speci fic HMT has a particular substrate specificity ; each enzyme methylates specific residues on specific histo nes. For example, DOT! L methylates Lys 79 of histone HJ ,' and G9a methylates Lys 9 of histone HJ and Lys 27 iu vitro, 21 although methylation on proteins other than histoncs has been reported. 11 PRMTs are able to methylate arginine residues of a variety of protein substrates, including histones. To determine the proper substrates for ea ch HMT iu vitro, a collection ofi-IMTs we re tested against all avail able histone substrates. Methyltransferase assay for G9a was also performed in a Flash Plate. The reaction was performed under the same conditions as in the HotSpot assay, but using biotinylatcd HJ ( 1-2 1) (AnaSpec). After the termination of the reactio n by the addition of 0.1 mM SAH, the reaction was transferred into the Flash Plate (Perkin Elmer) and counted by TopCount (PerkinEimcr). The follow-up hit co nfirmation was performed in a I 0-dose IC 50 mode with a threefold serial dilution starting at 100 J.IM under the same condition with the primary screening.
RESULTS
Substra te Specificity
The HotSpot format measures total methylation of a substrate by direct measurement of the filter-bound tritiated substrate, without the need for coupling enzymes or antibodies. Therefore, any substrate can be used label-free. This represents a major advantage over othe r detection methods that require methylation-specific antibodies or peptide modifications such as biotinlabeled peptides in SPA assays and sequence manipulation in the mobil ity-shift assay . In addition, this radioisotope-based format is not affected by compound fluorescence or by the inhibition of coupling enzymes, the two causes of false positives that arc commonly Figure 1 shows the progress curves for the SUV39H2 methyltransfcrasc reaction, as an example, plotted against time at 5 ~1M of peptide substrate and varied concentrations of SAM. The reaction was linear up to 60 min at most SAM concentrations, or 90 min at I J.!M SAM. Similar experiments were performed at different concentrations of the peptide substrate with varying SAM concentrations. Taking the slope of the initial linear portion (signal/ timc=velocity), velocities were plotted against SAM concentrations ( Fig. 2A) or peptide substrate concentrations (Fig . 28} to produce the Michaclis-Mcntcn plots. The Km values for SAM were not changed significantly by changing the peptide substrate concentrations (Fig.  2A) . Similarly, the Km values for the peptide substrate did not change over any SAM concentrations tested (Fig. 28) . To analyze further, the 4 ASSAY and Drug Development Technologies xxxx 20 13 double reciprocal of Fig. 2A was plotted in Fig. 2C . As shown, lines converged at one point to the left of they-axis. This pattern excludes a possibili ty of double-displacement reactions (or Ping-Pong; first, the substrate/product must leave before second substrate binding), which would display parallel lines in double-reciprocal plots. 29 Therefore, the SUV39fl2 methyltransferase reaction must be a random-ordered or compulsory-ordered Bi-Bi reaction, which means that SUV39H2 fo rms a ternary compl ex of the SUV39H2/SAM/ peptide substrate. At this point, it is difficult to distinguish between the two mechanisms: random ordered or compulsory ordered. To obtain accurate constants, a global-fit analysis was performed using GraFit softwa re with the ternary comp lex equation (Eq. 1; Fig. 2D ). Global fits weigh equally on all data points; therefore, it is more reliable than the traditional graphical method, which is highly affected by imprecise low-activity data points. The global fits revealed that the K,.. value of SUV39H2 for SAM was 1.27 J.!M, and that for the peptide was 9.9 J.!M (Fig. 2D ). Further studies with protein or methylated substrates arc needed to understand the mechanism of the SUV39H2 reaction in more detail, to determine, for example, whether the reactio n is processive or not (i.e., different substrates with protein and/or methylated substrate, processive or not). The kinetic constants for other HMTs were determined by similar ex periments. Most methyltransfcrase reactions were linear with time up to 60 min , and others for even longer up to 90-120 min. Taking slopes of the in itial linear portion of the reaction progress curves, the Michaelis-Menten plots were obtained for other HMTs with their corresponding substra tes. The obtained K,.. values by global fit arc summarized in Table 2 Table 2 ). The kinetic constants of alternative substrates with the listed HMTs as well as the kinetic characterization of additional HMTs were determined. In general, the K,.. values for the protein substrate were low and difficult to obtain accurately. Thus, the SAM K'" values were obtained at a fixed substrate concentration ( Table 3 ). The SAM K'" values at fixed substrate concentrations fall in a simil ar range to those in Table 2 , and are in generally a good agreement with reported values obtained by radioisotope-based assays. 32 
Co mpou n d Evalua tion
The known mcthyltransferase inhibitors were tested in this assay format against selected HMTs: G9a , SET7, and PRMT5. The compounds tested were SAil (5-Adcnosyi-L-homocysteine or AdoHcy), sincfungin, chactocin, and BIXO 1294. SAH is a product of the methyltransferase reaction, which inhibits HMTs competitively with respect to SAM. Sincfungin, a fungal compound, is an analog of cofactor SAM, chaetocin, an inhibitor of SUV39, and BIXOI294, an inhibitorofG9a/GLP. 33 -3~ As shown in Fig. 3 using the HotSpot rad ioisotope-based assay under the standard conditions. SAH and sinefungin each differed in thei r inhibition, although both compounds were SAM competitive: IC 50 values of I.41JM and I 0 11M for G9a, 290 11M and 2.41JM for SET7, and 1.21JM and 306 nM for PRMT5, respectively, with a peptide substrate. Chaetocin inhibited both G9a and SET7 weakly with a peptide substrate IIC 50 values of I81JM and 540 11M, respectively), but did not inhibit PRMT5. Interesti ngly, the G9a inhibitor BIX01294 also weakly inhibited SET7 and PRMT5 with a peptide substrate, but did not inhibit with a protein substrate. The IC 50 value of BIXO 1294 for G9a with a peptide substrate was 5.31JM (Fig. JA) , slightly higher than that reported. 35 To va lidate the G9a assay with a peptide substrate in HotSpot, the G9a assay was also performed in the FlashPlate fo rmat with 0.51JM of biotinylated H3 ( 1-2 1) peptide at I 11M SAM. The 1( 50 value of BIXO 1294 was obtained with 5.0 11M, comparable with the value obtained with HotSpot (Fig. JA) .
When the histone H3 protein was used as a substrate, the IC 50 values were shifted up for most compounds, especially for BIXO 1294 (Fig. 38, D, F) . These results suggest that the Km value fo r the histone protein was lower than that of the peptide substrate, thus making it more difficult for BIX0 1294 to displace the histone protei n.
Since BIXO 1294 has been reported as a peptide substratecompetitive and SAM-uncompetitive inhibitor,n lower peptide (0.5 1JM) and higher SAM ( 10 11M) concentrations were tested (Fig. 4A) . Under this condition, the IC 50 value was shifted to a lower value, 2.2 1JM, which is similar to that obtained by a mass spectrometry-based assay. 34 On the other hand, the IC 50 value ofSAH was shifted 10-fold higher when the SAM concentration was increased to I 0 11M (Fig. 4A ). This shift was expected for a SAM competitive inhibitor. G9a can mono-and dimethylate the lysine 9 residue on histone H3. Therefore, dimethylation was monitored using monomethylated lysine 9 peptide as a substrate. As shown in Fig. 48 , the IC 50 value of BIXO 1294 was Kinetic constants were determined at a concentration of SliM for histone or 0.05 mg/ml for core histone.
shifted about fivefold lower to I .311M compared to that with nonmethy lated substnte (Fig. JA) , a lthough the activity was < 1/ 10. Trimethylation was minimal when using dimethylated lysine 9 peptide as a substrate under this condition. On the other hand, the IC 50 value of SAH was not changed significantly (Figs. JA and 4B) .
Overall, the data indicate that the HotSpot format is ideal for compound profiling, since a ny substrate can be used without a ny modifications. In addition, the IC 50 values obtained with this format are sim ilar to those from mass spectrometry-based assays, which are the most reliable methods for detecting the methyl transfe rase reactions.
ASSAY and Drug Development Technologies xxxx 2013
Compound Screening Low-cost and robust assays with minima l false positives have been desired for I-ITS, especially for difficu lt or expensive enzymes. DOT! L is an attractive drug ta rget; however, it needs a histone octamer or nucJ eosomcs as a substrate for enzyme activity, and monomer histone or peptide substrates do not work. Thus, screening against DOTIL is costly and difficuli to run with certain assay fo rmats. We screened LOPAC (Sigma), a small library of I ,280 compounds, against DOTIL with core histone as the substrate in a miniaturized goldstandard radioisotope-based assay where the cost of the radioisotopelabeled cofactor and its waste, as well as that of the other reagents, could be minimized. Althoug h most ~fMT assays in this fo rmat have Z'-factors 3 G of >0.6, the Z'-factor was 0.52 fo r the DOT! L assay, and the Signal:Backgrou nd ratio was 4.3 (Supplementary Table 52 ).
We identified three compounds that showed more than 70% inhibition against DOT! L-two of these were sura min and its analog, while the other was L-cysteine sulfin ic acid. The follow -up hi t confi rmation was performed by cherry-picking o f three compounds under the same condition of primary screen ing. Then, suramin and its 2 analogs, NF 110 and NF 449, were profiled against 17 HMTs in our panel. The obtained IC 50 values a re summarized in Table 4 . Suramin and NF 449 showed si milar inhibition patterns, whereas NF 110 showed little activity. In teresti ngly, activities of many HMTs were increased by suram in and NF 449 at low concentTations of compou nds, while inhibited a t h ighe r concentrations. The degree o f such a ctiva tions was not consistent; thus, the IC 50 values may not be accu rate; these were expressed in italic letters. The reason for such activations is not clear, whether there was real enzyme activation, or were false signals caused by compound aggregation, etc. Since su ra min is a relatively large molecule, it could possibly have caused compound aggregation involving substrates and/or enzymes. Methyltransferases that were consistently inhibited by suramin (wi tho ut a pparent activation) are DOTIL, NSD2, and PRMT4 with IC 50 values at a low 11M range.
DISCUSSION
The radioisotope-based miniaturized filter-bindi ng assay, HotSpot platform, was initially developed for kinase assays, but has since been successfully applied to other transferase enzyme classes to serve markets for ui-ITS, large-scale IC 50 determinations, a nd selectivity/ toxicity profiling in drug discovery. 23 · 24 In this study, we have modified this platform fo r ~fMT assays using tritium-labeled SAM as a cofactor, and demonstrated that compou nd p rofiling, kinetic studies, and I-ITS can be performed cost effectively with this system.
The currently available assay formats for HMTs have various li mitatio ns. zG The traditiona l methods a re gel-based radioisotope assays o r mass spectrometry-based assays, 37 wh ich directly measure methylation on the substrate. Mass spectrometry-based assays are the most reliable assays, and therefore detailed kinetic studies still employ these formats. However, apply ing high-throughput formats with these assays is difficult and/or requires expensive instrumentation.
Another radioisotope-based assay, first reported by Rathert et a1.,
36
used streptavidin-coated FlashPlates to capture the biotinylated peptide substrate, which, while bound to the plate, was enzymatically labeled with tri tiated SAM. This is a continuous assay and may be applied to HTS. Asi de fro m the requirement fo r biotinylated peptides, it is ha rd to control the substrate concentrations in this system, making the determin ation of ki netic parameters problematic.
Most popular assays a re antibody based a nd employ a variety of detection systems, incl udi ng bioti n-avidin, CLOT, and ELISA. The CLOT assay is a homogeneous assay in which the methylation of a biotinylated histone peptide is measured through methyla tionspecific antibody-based detection, in conjunction with strcptavidi ncoated do nor and secondary antibody-coated AlphaScreen acceptor beads. 39 The limitation of such a ntibody-based detection systems is the need for antibodies speci fi c for particular methylation sites as well as fo r mono-, d i-, or trimethyla tion. Therefore, it is di ffic ul t to profile a compound against a wide selection of HMTs with different substrates{ methylation sites or to perfo rm kinetic studies. While the above methods detect methylation of (mostly) peptide substrates, another a pproach is to detect AdoHcy (5-ade nosyl-homocystcine, or SAH), the reaction product de rived from AdoMet (SAM). Graves ct a /. 40 have described a competitive fluorescence pola rization (FP) assay that uses a n antibody against AdoHcy and a fl uoro phore-conjugated AdoHcy. The fl uorescent AdoHcy conj ugate is bound by the a ntiAdoHcy-antibody to prod uce a high FP complex: The AdoHcy produced in the methy lation process displaces the fl uorescent tracer, resulting in a decrease of the FP signal. Although the assay is homogenous a nd continuous, its sensitivity is low. Collazo et a/. 41 have reported an enzyme-coupled assay that utilizes 5-adenosylhomocysteine hydrolase (SAHH) to hydrolyze the methyltransferase product, AdoHcy, to homocysteine (Hey) and adenosine (Ado), and adenosine deaminase to pull the reaction to completion. The Hey concentration is then determined through conjugation of its free sul fhyd ryl moiety to a th iol-sensitive flu orophore (Th ioGlo). One disadvantage of this assay is its sensitivity to thiol-based reduci ng agents (e.g., OTT or P- 
in general is the possibility of fa lse positives, wh ich are inhibitors of the coupling enzymes rather than the screening target, and the consequent need for counter assays fo r the coupling enzymes. In addition, the coupling enzyme should not be rate limiting to the overall reaction: SAini, however, is a very slow enzyme. A further disadvantage of the SAHH/ThioGio system, which applies equally to any system based on fl uorescence detectio n, is that fluo rescence or fluo rescence quenching from screening compounds may interfere with the assay. The mobili ty-shi ft assay 42 (Fig. J A) . Considering the competitive mode of BIXO 1294 inhibition with respect to SAH, 5-adenosyl-t-homocysteine.
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the peptide substrate and the K., for peptide (0.6 1JM in the Tab le 2), the K; value of BIX01294 is estimated as 570 nM, in good agreement with published data at low peptide conccntrations. 35 Since it has been reponed that BIXO 1294 is competitive with the peptide substrate, but uncompctitive with SAM, 33 the IC 50 value was determined under lower peptide and higher SAM concen trations. Under this condition [0.5 1JM 113 ( 1-2 1) at 10 11M SAM], the IC 50 value was 2.2 J.!M (Fig. 4A) , shifted about twofold, whic h is close to the value obtained by mass spcctromctry.3~ Interest ingly, the IC 50 value was shifted about fourfold lowe r whe n the s ubstrate was monomethylated (Figs. JA vs. 48) . However, the IC 50 values a rc still higher than those compared to the values obtained by an SAHH-cou pling assay or CLOT assay.J 5 In assays using the Alpha LISA technique, the IC 50 value of BIXO 1294 against G9a (2.21JM) was a lso higher (PerkinElmcr, AlphaLISA Technical Note #2). We have performed another radioisotope-based assay using strcptavidi n-eoatcd FlashPiate with biotinylated histone 113 peptide, and obtained similar results to those from the HotSpot assay. When using histone H3 protein as substrate, the IC 50 value was shifted 80-fold higher (Fig. JB) . These sh ifts may be caused by the c hange in binding affinity to substrates, since BIX0 1294 is a competitive inhibitor with respect to the peptide substra te.JJ As it is expected that the binding a ffi n ity would increase for a protein substrate relative to a peptide, the inc reased IC 50 value for a peptide/prote in competitive inhibitor would make sense, consistent with a very low K, value for the protein substrate. In fa ct, it was very hard to obtain the K, values for the protein substrate for most HMTs. Shinkai a nd Tachibana 44 have a lso observed tha t the inhibi tion of G9a by BIXO 1294 is robust if an H3 N-tcrminal ol igopcptide is used as a substrate for the in vitro methyl transferase assay, but is not significant (no inhibition at IO J.!M) if a fu ll -le ngth 113 is used. It would be interesting to determine the processivity of G9a mcthyltransfcrasc activity with a protein substra te in the presence and absence of BIXO 1294. Further studies are needed to elucidate the mecha nism of action of BIXO 1294 (and recently fo und analogs) not on ly with a peptide substrate, b ut with a protein substrate as well. The data in this study demonstrate the capability of the HotSpot platform whe n applied to the histone methyltransfcrasc assays. The data quality is sufficient for all drug discovery activities, fro m ul trahigh throughput sc reening to compound profiling against a large collection of HMTs and kinetic studies. Advantageous featu res of this pla tform for drug discovery include the absence of interference from nuoresccnt co mpounds and the e limination of the need for coupling enzy mes, speci fi c antibodies, or specifically modified peptide substrates. This enables substrate profiling as we ll as the determinatio n of total methylation with unidentified protein substrates or with known pcptides/protcins at undetermined methylation sites. Taking these advantages, one can perform compound screening at K.,, o f peptide o r SAM, or profiling under conditions close to in vivo usi ng nuclcosomcs as the substrate. One concern may be data reproducibility when using nucleosomes or core histone as a substrate, since they arc purified from na tural sources (Hcla or chicken, respectively). Although their methyla tion states are unknown, data reproducibility was satisfa ctory (the data consistency of the IC 50 values for SAil was
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shown in Supplementary Table SJ) ; presumably, preparations are well homogenized and minima l lot-to-lot variability. Since the platform is a miniaturized radioisotope-based assay, it reduces the cost by minimizing reagent usage. This is a considerable advantage especially for difficult or expensive enzymes and substrates. We performed a small -library !ITS against DOT I L, which requires a special substrate, core histones, and suramin was identified as a DOTIL inhibitor. Subsequently, suramin was profil ed against 17 methyltransferases with different substrates. Since the major advantage of this assay form at is that it can be applied universally to methyltransfcrascs regardless of the substrate, it is suitable fo r profilin g. Although the activities of some IIMTs arc increased at low concentrations, mcthyltransferases that were consistently inhibited (without appare nt activation) by suramin a rc DOT I L, NSD2, and PRMT4 with IC 50 values at a low J.!M range ( Table 4) . This is the first finding that suramin inhibits DOT I Land NSD2 activities, although it has been reported very recently that a few IIMTs a rc inhibited by a suramin analog using a peptide as the substrate. 45 Suramin is an old drug that has been used fo r the treatment of trypanosomiasis a nd is known as a n antagonist of P2 receptors; recently, the application of suramin to cancer treatment has been explorcd. 46 It would be interesting to determine the effects of suramin on methylatio n states at the cellular level, especially in cancer cell lines.
